Skip to main content
. 2018 Sep 20;15(2):295–311. doi: 10.1080/15548627.2018.1517073

Figure 5.

Figure 5.

S130 induces cell death through inhibiting the activity of ATG4B. (A) HeLa cells were treated with 0–25 μM of S130 in the presence or absence of 40 μM necrostatin-1, 10 μM of Z-VAD-FMK or 10 μM of CQ for 48 h, and cell viability was measured with CCK8. (B) Cell viability analysis of ATG4B KO HeLa, WT HeLa and ATG4B OE HeLa cells treated with 0–25 μM of S130 for 48 h. (C) Immunoblot analysis of WT HeLa and ATG4B KO HeLa cells treated with S130 (10 μM) for 24 h. (D) Cell viability analysis of ATG4B KO HeLa cells expressing ATG4B, empty vector, ATG4BC74S, or ATG4A treated with 0–25 μM of S130 for 48 h. (E-F) Immunoblot analysis of ATG4B KO HeLa cells overexpressing empty vector or ATG4B with quantification of the protein level of LC3-I and C-CASP3(E), or ATG4BC74S and ATG4A (F) treated with or without S130 (10 μM) for 24 h. The bands in ATG4B KO HeLa cells indicate the pro-LC3. Data are presented as mean ± SEM from 3 individual experiments. *P < 0.05, **P < 0.01, ***P < 0.001.